Phaseline

Companies › Incyte

Incyte: clinical trials, targets and expected readouts

19 active drug programs in 319 registered trials: 184 Phase 2, 91 Phase 1, 42 Phase 3, 2 Phase 4; Oncology, Other, Immunology, Hematology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ruxolitinib
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor
JAK1, JAK2, JAK3, TYK2Phase 3NonSegmental Vitiligo; Hidradenitis Suppurativa; Atopic Dermatitis; Graft-versus-host Disease (GVHD) …Nov 2026
INCA033989
unclear - mechanism not stated in registry
–Phase 3Essential Thrombocythemia; Healthy Participants; Myeloproliferative NeoplasmsNov 2026
povorcitinib
JAK1 inhibitor
JAK1Phase 3Hidradenitis Suppurativa (HS); NonSegmental Vitiligo; Prurigo Nodularis; Moderate to Severe Asthma …Nov 2026
INCA33890–Phase 3CRC (Colorectal Cancer); Solid TumorsJan 2027
INCB161734
KRAS G12D inhibitor
KRASPhase 3Solid Tumors; Healthy ParticipantsJan 2027
INCB123667
Cyclin-dependent kinase 4/6 inhibitor (CDK4/6 inhibitor)
–Phase 3Ovarian Cancer; Renal Impairment; Hepatic Insufficiency; Solid TumorsJan 2027
Axatilimab
Macrophage colony stimulating factor receptor inhibitor
CSF1RPhase 3Chronic Graft-versus-host-disease; TNBC - Triple-Negative Breast Cancer; Hodgkin Lymphoma; Chronic Graft Versus Host Disease …Jan 2027
Lenalidomide
CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator
CRBN, DDB1, CUL4A, RBX1Phase 3Large B-Cell Lymphoma; Diffuse Large B-cell Lymphoma; Diffuse Large B Cell Lymphoma; Newly Diagnosed …Apr 2027
Tafasitamab
B-lymphocyte antigen CD19 binding agent
CD19Phase 3Large B-Cell Lymphoma; Diffuse Large B-cell Lymphoma; Follicular Lymphoma; Hematologic Malignancies …Apr 2027
Itacitinib
Tyrosine-protein kinase JAK1 inhibitor
JAK1Phase 2B-Cell Malignancies; Systemic Sclerosis; Diffuse Large B Cell Lymphoma; Acute Lymphoblastic Leukemia …Nov 2026
Parsaclisib
PI3-kinase p110-delta subunit inhibitor
PIK3CDPhase 2B-Cell MalignanciesNov 2026
INCB000928
ALK2 (activin receptor-like kinase 2) inhibitor
ALK2Phase 2Fibrodysplasia Ossificans Progressiva (FOP)Jul 2027
INCB099280–Phase 2Cutaneous Squamous Cell Carcinoma; Advanced Solid Tumor–
INCB186748
KRAS G12D inhibitor
KRASPhase 1Solid TumorsMar 2027
INCB057643–Phase 1MyelofibrosisApr 2027
INCA035784–Phase 1Myeloproliferative NeoplasmsMar 2028
INCA036873–Phase 1Solid TumorsAug 2028
INCB160058–Phase 1Myeloproliferative NeoplasmsOct 2028
INCA036978–Phase 1Myeloproliferative NeoplasmsMay 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT00098475LenalidomidePhase 3DS Stage I Multiple MyelomaOncologyNov 2008
NCT04460248LenalidomidePhase 2Diffuse Large B Cell LymphomaOncologyFeb 2022
NCT03674047RuxolitinibPhase 2Other CancerOncologyDec 2022
NCT05182957LenalidomidePhase 2Relapsed/Refractory Peripheral T-cell LymphomaOncologyDec 2023
NCT03333187RuxolitinibPhase 2Bone Marrow FibrosisOncologyOct 2024
NCT06719024RuxolitinibPhase 2VitiligoImmunologyJun 2025
NCT04737889LenalidomidePhase 2Primary Central Nervous System LymphomaOncologyJun 2025
NCT03610971RuxolitinibPhase 2Chronic Phase Chronic Myeloid LeukemiaOncologySep 2025
NCT04551131RuxolitinibPhase 1Hemophagocytic LymphohistiocytosisHematologyNov 2025
NCT06752694RuxolitinibPhase 2Aplastic AnemiaHematologyJan 2026
NCT04789850ItacitinibPhase 2Systemic SclerosisImmunologyFeb 2026
NCT06261021RuxolitinibPhase 2Discoid Lupus ErythematosusImmunologyFeb 2026
NCT06399029RuxolitinibPhase 2ExanthemaOncologyApr 2026
NCT03104842LenalidomidePhase 2Multiple MyelomaOncologyMay 2026
NCT03500445LenalidomidePhase 2MyelomaOncologyJun 2026
NCT07725432RuxolitinibPhase 2Immune-related Vitiligo-like-DepigmentationImmunologyJul 2026
NCT06756152RuxolitinibPhase 2Biphenotypic Acute LeukemiaOncologyJul 2026
NCT03836014LenalidomidePhase 3Multiple Myeloma in RelapseOncologyJul 2026
NCT06762431LenalidomidePhase 1Chronic Lymphocytic Leukaemia (CLL)OncologyAug 2026
NCT07588139RuxolitinibPhase 1Healthy ParticipantsOtherSep 2026
NCT07588139povorcitinibPhase 1Healthy ParticipantsOtherSep 2026
NCT05888844INCB099280Phase 2Cutaneous Squamous Cell CarcinomaOncologySep 2026
NCT05879822INCB099280Phase 2Advanced Solid TumorOncologySep 2026
NCT07814404INCB161734Phase 1Healthy ParticipantsOtherOct 2026
NCT04509700RuxolitinibPhase 2B-Cell MalignanciesOncologyNov 2026
NCT04509700ParsaclisibPhase 2B-Cell MalignanciesOncologyNov 2026
NCT04509700ItacitinibPhase 2B-Cell MalignanciesOncologyNov 2026
NCT07448155INCA033989Phase 1Healthy ParticipantsOtherNov 2026
NCT03681561RuxolitinibPhase 1Hodgkin LymphomaOncologyNov 2026
NCT06517017LenalidomidePhase 2Multiple MyelomaOncologyNov 2026
NCT03980171LenalidomidePhase 1Follicular LymphomaOncologyNov 2026
NCT04174196LenalidomidePhase 2PlasmacytomaOncologyNov 2026
NCT05851443povorcitinibPhase 2Moderate to Severe AsthmaRespiratoryNov 2026
NCT06199427RuxolitinibPhase 2Inborn Errors of ImmunityImmunologyNov 2026
NCT05335018LenalidomidePhase 2Relapsed/refractory Diffuse Large B Cell LymphomaOncologyNov 2026
NCT05491226AxatilimabPhase 2TNBC - Triple-Negative Breast CancerOncologyDec 2026
NCT05979363LenalidomidePhase 2Plasma Cell LeukemiaOncologyDec 2026
NCT05992597LenalidomidePhase 2Rituximab, Lenalidomide, Zebutinib ,Mantle Cell LymphomaOncologyDec 2026
NCT06547944LenalidomidePhase 1Chronic Lymphocytic LeukemiaOncologyDec 2026
NCT03223610LenalidomidePhase 1LymphomaOncologyDec 2026
NCT07049575RuxolitinibPhase 1Hidradenitis SuppurativaImmunologyDec 2026
NCT07238712RuxolitinibPhase 2Acute Myeloid Leukemia (AML)OncologyDec 2026
NCT06770842RuxolitinibPhase 2Primary Myelofibrosis (PMF)OncologyDec 2026
NCT03286530RuxolitinibPhase 2Acute Myeloid LeukemiaOncologyDec 2026
NCT05723055AxatilimabPhase 2Hodgkin LymphomaOncologyDec 2026
NCT01208662LenalidomidePhase 3Multiple MyelomaOncologyDec 2026
NCT02544308LenalidomidePhase 3PlasmacytomaOncologyDec 2026
NCT02523040LenalidomidePhase 2Langerhans Cell Histiocytosis (LCH)OncologyDec 2026
NCT04009109LenalidomidePhase 2Myeloma, MultipleOncologyDec 2026
NCT00378105LenalidomidePhase 1Multiple MyelomaOncologyDec 2026
NCT02573896LenalidomidePhase 1NeuroblastomaOncologyDec 2026
NCT01054196LenalidomidePhase 1Multiple MyelomaOncologyDec 2026
NCT02334865LenalidomidePhase 1Partial Response of Multiple Myeloma or Plasma Cell LeukemiaOncologyDec 2026
NCT06212999povorcitinibPhase 3Hidradenitis Suppurativa (HS)ImmunologyDec 2026
NCT05817955RuxolitinibPhase 2MDS/MPNOncologyDec 2026
NCT04430894LenalidomidePhase 2Multiple MyelomaOncologyDec 2026
NCT05821088TafasitamabPhase 2Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin LymphomaOncologyDec 2026
NCT05351593TafasitamabPhase 1CNS LymphomaOncologyDec 2026
NCT01863550LenalidomidePhase 3Plasma Cell MyelomaOncologyDec 2026
NCT06504199LenalidomidePhase 2Mantle Cell LymphomaOncologyDec 2026

The 60 nearest readouts of 319 trials; the rest in the app.

From the company's SEC filings

Cash of $3.3bn on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Targets

JAK1 (3) KRAS (2) JAK2 (1) JAK3 (1) TYK2 (1) CSF1R (1) CD19 (1) CRBN (1) DDB1 (1) CUL4A (1) RBX1 (1) PIK3CD (1)

Companies with the same targets

AbbVie Pfizer Revolution Medicines Eli Lilly Sun Pharmaceutical Industries Alfasigma Takeda LEO Pharma Eisai Bristol-Myers Squibb

Companies built like this

Beijing InnoCare Pharma Tech Jazz Pharmaceuticals Exelixis Genmab Shandong Suncadia Medicine

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.